OvaScience (NASDAQ: OVAS) is one of 189 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it compare to its competitors? We will compare OvaScience to similar companies based on the strength of its valuation, dividends, institutional ownership, earnings, risk, profitability and analyst recommendations.
Volatility and Risk
OvaScience has a beta of 3.73, suggesting that its share price is 273% more volatile than the S&P 500. Comparatively, OvaScience’s competitors have a beta of 1.47, suggesting that their average share price is 47% more volatile than the S&P 500.
This table compares OvaScience and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and price targets for OvaScience and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
OvaScience currently has a consensus price target of $8.00, indicating a potential upside of 589.66%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 11.95%. Given OvaScience’s higher probable upside, equities research analysts plainly believe OvaScience is more favorable than its competitors.
Earnings & Valuation
This table compares OvaScience and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|OvaScience Competitors||$217.40 million||-$39.40 million||-64.99|
OvaScience’s competitors have higher revenue and earnings than OvaScience. OvaScience is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
55.1% of OvaScience shares are owned by institutional investors. Comparatively, 49.2% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 9.5% of OvaScience shares are owned by company insiders. Comparatively, 14.8% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
OvaScience competitors beat OvaScience on 8 of the 13 factors compared.
OvaScience, Inc. is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue. The Company’s AUGMENT treatment is designed to improve egg health by supplementing a mitochondrial deficiency. With the AUGMENT treatment, energy-producing mitochondria from a patient’s own EggPC cells are added to the patient’s mature eggs during the in vitro fertilization process to supplement the existing mitochondria. Its OvaPrime treatment is a fertility treatment designed to replenish a woman’s ovary by increasing her egg reserve using her own EggPC cells. Its OvaTure treatment is a fertility treatment that seeks to create mature fertilizable eggs in vitro from a woman’s own EggPC cells without the need for hormone hyperstimulation.
Receive News & Ratings for OvaScience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience and related companies with MarketBeat.com's FREE daily email newsletter.